The agreement provides for Gene Logic to receive success-based milestone payments for each drug candidate Roche returns to clinical development. In addition, Gene Logic will receive royalties for each marketed drug.
The agreement also provides Gene Logic the option to receive an exclusive license to any drug candidate that Roche chooses not to pursue, in which case Roche will receive success-based milestone and royalty payments.
Applying a unique, diverse set of drug discovery technologies in parallel, Gene Logic’s drug repositioning program evaluates drug candidates for potential utility across a wide spectrum of disease indications.
“We see Gene Logic’s program as an interesting and innovative option for Roche in our effort to continually enhance our clinical pipeline,” commented Dr Jonathan Knowles, president of Global Research at Roche. “We believe Gene Logic’s novel approach to quickly and systematically identify new indications for drugs will help us to create potential break-through medicines for the benefit of patients worldwide.”